CPLX2 — Complexin 2

CPLX2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CPLX2 — Complexin 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CPLX2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Complexin 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q31.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10857</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>605738</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000128487</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75178</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Alzheimer's Disease](/diseases/alzheimers-disease)</td>
<td>CPLX2 levels reduced in AD hippocampus; involved in synaptic dysfunction</td>
</tr>
<tr>
<td class="label">[Parkinson's Disease](/diseases/parkinsons-disease)</td>
<td>Altered SNARE regulation affects dopaminergic transmission</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>Mutations affect release probability and seizure threshold</td>
</tr>
<tr>
<td class="label">Schizophrenia</td>
<td>CPLX2 dysregulation in prefrontal [cortex](/brain-regions/cortex)</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Mutant [huntingtin](/proteins/huntingtin-protein) affects complexin function</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td

...

CPLX2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CPLX2 — Complexin 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CPLX2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Complexin 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q31.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10857</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>605738</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000128487</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75178</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[Alzheimer's Disease](/diseases/alzheimers-disease)</td>
<td>CPLX2 levels reduced in AD hippocampus; involved in synaptic dysfunction</td>
</tr>
<tr>
<td class="label">[Parkinson's Disease](/diseases/parkinsons-disease)</td>
<td>Altered SNARE regulation affects dopaminergic transmission</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>Mutations affect release probability and seizure threshold</td>
</tr>
<tr>
<td class="label">Schizophrenia</td>
<td>CPLX2 dysregulation in prefrontal [cortex](/brain-regions/cortex)</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Mutant [huntingtin](/proteins/huntingtin-protein) affects complexin function</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CPLX2 modulators</td>
<td>Small molecules to enhance or inhibit SNARE regulation</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated CPLX2 delivery for neuroprotection</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">SNARE Complex</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">Synaptotagmin</td>
<td>Ca²⁺-dependent</td>
</tr>
<tr>
<td class="label">Munc13</td>
<td>Competition</td>
</tr>
<tr>
<td class="label">Munc18</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Exogenous CPLX2</td>
<td>SNARE complex</td>
</tr>
<tr>
<td class="label">SNARE stabilizers</td>
<td>Fusion machinery</td>
</tr>
<tr>
<td class="label">Synaptotagmin activators</td>
<td>Ca²⁺ sensor</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

Cplx2 — Complexin 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

CPLX2 (Complexin 2) is a neuronal gene encoding a small soluble protein that regulates vesicle fusion by synaptic binding to the SNARE complex. It plays a critical role in modulating neurotransmitter release probability and synaptic plasticity. [@rizo1998]

Gene Information

Function

Complexin 2 is a cytosolic protein that regulates SNARE complex assembly:

• SNARE Regulation: Binds to assembled SNARE complexes to regulate fusion
• Fusion Modulation: Facilitates both spontaneous and evoked release
• Synaptic Plasticity: Regulates short-term plasticity (facilitation/depression)
• Neuroprotection: Complexins have neuroprotective roles in neurodegeneration
• Alternative Splicing: Produces multiple isoforms with distinct functions

Disease Associations

Expression

CPLX2 is expressed in:

• Cerebral cortex (layer 2/3, 5 pyramidal neurons)
• [Hippocampus](/brain-regions/hippocampus) (CA1-CA3, dentate gyrus)
• Cerebellum (Purkinje cells)
• Basal ganglia
• Olfactory bulb
• Retina

Therapeutic Targeting

Key Publications

Complexin function in neurotransmitter release - Nat Neurosci (2001) - PMID: 11436640(https://pubmed.ncbi.nlm.nih.gov/11436640/)

CPLX2 in Alzheimer's disease - J Neurosci (2009) - PMID: 19244523(https://pubmed.ncbi.nlm.nih.gov/19244523/)

Complexin and synaptic plasticity - [Neuron](/entities/neurons) (2012) - PMID: 22958824(https://pubmed.ncbi.nlm.nih.gov/22958824/)

CPLX2 mutations in epilepsy - Brain (2015) - PMID: 25840038(https://pubmed.ncbi.nlm.nih.gov/25840038/)

See Also

• [SNAP25 Gene](/proteins/snap25-protein)
• [STX1A Gene](/proteins/stx1a-protein)
• [VAMP2 Gene](/proteins/vamp2-protein)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)

Molecular Mechanisms

Structure and SNARE Binding

Complexin 2 is a small (~150 aa) cytosolic protein:

• [N-terminal Domain*: Binds to assembled SNARE complexes](/genes/ar)
• [Central Alpha-helical Domain*: Forms a parallel alpha-helix with SNAREpins](/genes/ar)
• [C-terminal Domain*: Anchors complexin to the plasma membrane via lipid binding](/genes/ran)
• Zinc Finger Region: Some isoforms contain zinc-binding motifs

Dual Function in Fusion

Complexin exhibits both inhibitory and facilitatory functions:

• [Inhibitory Function*: Prevents full SNARE assembly before Ca²⁺ influx](/events)
• [Facilitatory Function*: Upon Ca²⁺ binding to synaptotagmin, complexin releases inhibition](/genes/nct)
• [Conformational Switch*: Ca²⁺ triggers transition from inhibitory to facilitatory state](/genes/ran)
• [Fusion Pore Regulation*:](/entities/fus)Controls fusion pore opening and expansion

Protein Interactions

Splice Variants

• CPLX2-201: Full-length, predominant brain isoform
• CPLX2-202: Alternative C-terminus
• CPLX2-203: Testis-specific isoform

Role in Neurodegeneration

Alzheimer's Disease

CPLX2 dysfunction contributes to synaptic failure:

• Expression Reduction: 40-60% decrease in AD prefrontal cortex
• Synaptic Transmission: Impaired spontaneous release
• [Aβ](/proteins/amyloid-beta) Effects: [Aβ](/proteins/amyloid-beta) oligomers reduce complexin levels
• Therapeutic Potential: CPLX2 restoration may improve synaptic function

Parkinson's Disease

Dopaminergic synapses show specific vulnerabilities:

• SNARE Dysregulation: Alters vesicle fusion kinetics
• [Alpha-Synuclein](/mechanisms/alpha-synuclein) Interaction: α-syn may interfere with complexin function
• Therapeutic Strategies: Enhancing SNARE regulation

Huntington's Disease

mHTT affects synaptic function:

• mHTT Binding: Mutant [huntingtin](/genes/htt) sequesters CPLX2
• Synaptic Transmission: Reduced excitatory transmission
• Therapeutic Target: Releasing sequestered CPLX2

Schizophrenia

CPLX2 is a schizophrenia candidate gene:

• Expression Changes: Reduced in prefrontal cortex
• GABAergic Dysfunction: Affects inhibitory transmission
• Cognitive Deficits: Contributes to working memory impairments

Therapeutic Implications

Small Molecule Modulators

Gene Therapy Approaches

• AAV-CPLX2: Restoration of complexin levels
• Gene Editing: CRISPR-based approaches
• Protein Therapy: Cell-penetrant complexin peptides

Animal Models

Knockout Studies

• CPLX2 KO Mice: Viable with subtle behavioral deficits
• CPLX1/2 Double KO: Severe neurological phenotypes
• Conditional KO: Region-specific deletion reveals circuit roles

Transgenic Models

• CPLX2 Overexpression: Enhanced synaptic transmission
• Human CPLX2: Rescue of knockout phenotypes
• Disease Models: CPLX2 changes in AD/PD mouse models

Research Directions

• Single-Molecule Studies: Real-time observation of SNARE-complexin dynamics
• Cryo-EM Structures: High-resolution fusion intermediate visualization
• Biomarker Development: CPLX2 as synaptic integrity marker
• Therapeutic Screening: High-throughput compound screening

Clinical Significance

CPLX2 variants and disease:

• Epilepsy: Rare missense mutations cause early-onset seizures
• Psychiatric Disorders: Copy number variations include CPLX2
• Neurodevelopmental Disorders: Associated with intellectual disability

Background

The study of Cplx2 — Complexin 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

• [NCBI Gene: CPLX2](https://www.ncbi.nlm.nih.gov/gene/10857)
• [UniProt: CPLX2](https://www.uniprot.or- [Ge